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Background: As the population ages, more people are suffering from long-term health conditions (LTCs). Health
services around the world are exploring new ways of supporting people with LTCs and there is great interest in the
use of telehealth: technologies such as the Internet, telephone and home self-monitoring.
Methods/Design: This study aims to evaluate the effectiveness and cost-effectiveness of a telehealth intervention
delivered by NHS Direct to support patients with LTCs. Two randomized controlled trials will be conducted in parallel,
recruiting patients with two exemplar LTCs: depression or raised cardiovascular disease (CVD) risk. A total of 1,200
patients will be recruited from approximately 42 general practices near Bristol, Sheffield and Southampton, UK.
Participants will be randomly allocated to either usual care (control group) or usual care plus the NHS Direct
Healthlines Service (intervention group). The intervention is based on a conceptual model incorporating promotion of
self-management, optimisation of treatment, coordination of care and engagement of patients and general
practitioners. Participants will be provided with tailored help, combining telephone advice from health information
advisors with support to use a range of online resources. Participants will access the service for 12 months. Outcomes
will be collected at baseline, four, eight and 12 months for the depression trial and baseline, six and 12 months for
the CVD risk trial. The primary outcome will be the proportion of patients responding to treatment, defined in the
depression trial as a PHQ-9 score <10 and an absolute reduction in PHQ-9 ≥5 after 4 months, and in the CVD risk
trial as maintenance or reduction of 10-year CVD risk after 12 months. The study will also assess whether the
intervention is cost-effective from the perspective of the NHS and personal social services. An embedded qualitative
interview study will explore healthcare professionals’ and patients’ views of the intervention.
Discussion: This study evaluates a complex telehealth intervention which combines evidence-based components and
is delivered by an established healthcare organisation. The study will also analyse health economic information. In
doing so, the study hopes to address some of the limitations of previous research by demonstrating the effectiveness
and cost-effectiveness of a real world telehealth intervention.
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As the population ages, the priority for the UK National
Health Service (NHS) is increasingly to help people
manage long-term conditions (LTCs). Over 15 million
people in England have a LTC, and the treatment of
LTCs accounts for 70% of total healthcare expenditures.
Therefore, improvements in LTC management could
have major benefits in terms of patient health, quality of
life and use of NHS resources [1]. It is acknowledged
that there is a need to redesign services both to cope
with the increasing number of people needing healthcare
and to improve the standard of care being offered. The
Department of Health has developed a strategy for im-
proving the care of patients with LTCs that is based on
promoting better health by supporting self-care and pro-
viding responsive, high-quality services and case man-
agement for those with the greatest needs [2].
There is strong international interest in using new tech-
nologies such as the Internet, text messaging, telephone
support or remote monitoring to help patients with LTCs
[3]. There is a large body of research in this area, including
the Whole System Demonstrator project, a recent large-
scale cluster randomized controlled trial (RCT) conducted
in the United Kingdom [4]. The research evidence has been
summarised in a number of systematic reviews of telehealth
delivery for a variety of LTCs [5-18]. These reviews show
that the evidence of its effectiveness is stronger for some
conditions (for example, heart failure) than for others (for
example, diabetes). Furthermore, there is good evidence
that telehealth is feasible and can improve health-related
behaviour but a lack of evidence about mechanisms of ac-
tion, health outcomes, value for money, patient satisfaction,
impact on the use of healthcare services and acceptability.
The Healthlines Study aims to address these limitations.
The two RCTs—an economic evaluation and an em-
bedded qualitative study—described in this protocol are
being conducted in the context of a wider programme
of research known as the Healthlines Study. This trial is
a 5-year project funded by the National Institute for
Health Research (NIHR) Programme Grants for Applied
Research scheme (grant reference RP-PG-0108-10011).
The programme commenced in November 2009 and is
a collaboration between NHS Direct; the Universities of
Bristol, Sheffield, Manchester and Southampton; and
the Royal College of Surgeons in Ireland. The overall
aim of the programme is to design, develop and evaluate
telehealth interventions for patients with LTCs to be de-
livered by NHS Direct.
Methods/Design
Outline of trial design
We describe two linked, multicentre, parallel two-arm,
individually randomized trials involving two different pa-
tient groups: those with depression and those with raisedcardiovascular disease (CVD) risk. The study infrastruc-
ture, including participating general practices, research
staff and intervention staff, and the underlying theoret-
ical basis for the intervention are common across both
trials. However, the specific content of the intervention
package, data analysis and reporting are distinct. Herein-
after these trials are referred to as the “depression trial”
and the “CVD risk trial”. Figure 1 shows a flowchart sum-
marising participant recruitment and follow-up proce-
dures for each of the trials. The first two general practices
recruited into the study will act as a run-in phase during
which study procedures will be tested and refined before
patients are recruited from the remaining practices.
Alongside the RCTs, we will also carry out an economic
evaluation and an embedded qualitative study to explore
the acceptability of the intervention.
Trial aim and objectives
The aim of the trials is to determine the clinical efficacy
and cost-effectiveness of an NHS Direct–delivered tele-
health intervention to support patients with two exemplar
LTCs: depression and raised cardiovascular risk. Specific-
ally, the study will address the following research questions:
1. Does the intervention, in addition to usual primary
care, improve condition-specific clinical outcomes
compared with usual care alone?
2. Does the intervention have any effect on other
patient outcomes, including quality of life and
satisfaction with care?
3. What is the cost-effectiveness of the intervention in
each condition?
4. What is the acceptability of and compliance with the
intervention, and what are the facilitators of and
barriers to its delivery?
Settings
The trial settings will comprise approximately 42 gen-
eral practices in the environs of Bristol, Sheffield and
Southampton. Two practices will participate in the run-
in phase, and the remainder will be involved in the
main trials. The final number of practices will depend
on achievement of participant recruitment targets.
Inclusion criteria
In both trials, participants will be required to have
access to a telephone (landline or mobile), the Inter-
net and an e-mail address for personal use. Additional
inclusion criteria for the CVD risk trial are (1) age be-
tween 40 and 74 years on the date of invitation to partici-
pate, which is the age range for which CVD risk scores
have been validated and the same age range used for
the NHS Health Checks vascular screening programme;
(2) 10-year risk of a cardiovascular event ≥20% calculated
Figure 1 Flowchart of participant recruitment and follow-up procedures. CIS-R, Clinical Interview Schedule–Revised; CVD, Cardiovascular
disease; GP, General practice; PHQ-9, Patient Health Questionnaire.
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following modifiable risk factors: (a) current systolic
blood pressure (BP) ≥140 and suitability for home BP
monitoring, (b) body mass index ≥30 and (c) currently
smoking. Additional inclusion for the depression trial are
(1) age ≥18 years on the date of invitation to participate,
(2) confirmed diagnosis of depression using the Clinical
Interview Schedule–Revised (CIS-R) [20] and (3) Patient
Health Questionnaire (PHQ-9) score ≥10 [21]. Patients
who meet the inclusion criteria for both the raised CVD
risk and depression trials will be invited to take part in the
depression trial only. All inclusion criteria must be met for
inclusion in the study.
Exclusion criteria
Exclusion criteria applying to both trials are listed below:
 Bipolar disorder
 Psychotic illness
 Dementia or substantial cognitive impairment
 Severe learning disability
 Substance dependency
 Receiving palliative care
 Significant suicide risk
 General practitioner’s determination that
participation would cause distress (for example, due
to recent bereavement) Inability to communicate verbally in English sufficiently
to receive telephone-based support delivered in English.
(Patients who can communicate verbally in English but
are unable to read English will be eligible, provided that
they have a family member or friend who is willing and
able to translate written materials (such as information
sheets, consent forms and online material) for them.
Additional exclusion criteria for the CVD risk trial
are (1) established diagnosis of CVD, defined as his-
tory of heart attack, angina, heart failure, stroke or
transient ischaemic attack; (2) currently pregnant or
planning to become pregnant within the next 12
months; (3) patients who will be invited to participate
in the NHS Health Checks Programme during the
period of the trial (in cases where the local Primary
Care Trust has requested this); and (4) patients with
atrial fibrillation for whom high BP is their only modi-
fiable risk factor.
Additional exclusion criteria for the depression trial
are (1) currently receiving case management from a
specialist mental health worker; (2) currently receiv-
ing face-to-face, telephone or computerised cognitive-
behavioural therapy (CBT) or similar psychotherapy;
and (3) having given birth in the previous 12 months.
An individual will be excluded if any of the criteria
are met.
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Initial identification and sampling
In the CVD risk trial, potentially eligible individuals will
be identified using a search of general practice compu-
terised patient records. Patients whose records suggest
they have a raised CVD risk and at least one modifiable
risk factor will be selected. Raised CVD risk is defined as
QRISK2 10-year risk score ≥20% calculated using risk
factor information extracted from the patient’s record.
In the depression trial, potentially eligible patients will
be identified using two methods: records search and dir-
ect healthcare professional (HCP) referral. The search
will include patients who have consulted the doctor for
depression, low mood or other similar symptoms or who
have been prescribed antidepressants within the previous
2 months. It will exclude individuals with any of the
study exclusion criteria.
With direct healthcare professional (HCP) referrals,
the general practitioner (GP) or other HCP will identify
potentially eligible participants during patients’ consulta-
tions. The GP or other HCP will explain the study to the
patient and provide an invitation letter and the partici-
pant information sheet. If the patient is interested in tak-
ing part, the GP or other HCP will complete a referral
checklist and, with the patient’s permission, pass the pa-
tient’s contact details to the local research team.
In both trials, a random sample of the potentially eli-
gible patients derived from the records search or all of
the identified patients, whichever is the smaller group,
will be selected. The initial plan is to invite 250 and 300
patients per practice for the CVD and depression trials,
respectively, but this number will be revised based on
actual recruitment rates in the run-in phase and early
main trial practices to ensure that recruitment targets
are met. In both trials, GPs will be asked to review the
list of potentially eligible patients and exclude any pa-
tients felt to be unsuitable (for example, due to recent
bereavement).
Invitations and reminders
Practice staff will send patients identified in a records
search an invitation letter and participant information
sheet. Patients interested in participating will be asked
to respond directly to the research team, providing con-
tact details and consent for eligibility screening. Those
who do not wish to take part will be asked to return a
decline form. Practice staff will send one postal reminder
to individuals who have not yet responded 3 weeks after
the initial mailing and also have the option of using tele-
phone reminders if they wish. In the depression trial, in-
terested patients will also be asked to complete and
return a PHQ-9 questionnaire at this stage, which will
be used to make a preliminary assessment of the pa-
tient’s eligibility for the study.Confirmation of eligibility
Patients who reply to express an interest in participating
will be contacted by a member of the local research
team by telephone. The researcher will clarify with the
patient what taking part in the study will involve and
answer any questions. The patient’s ability to access the
Internet and e-mail will also be confirmed. Further eligi-
bility screening will then proceed in the two trials as
described next.
In the CVD risk trial, patients will be asked to attend
an appointment at their GP practice with a pretrained
practice nurse or healthcare assistant (HCA). The nurse
or HCA will take BP readings using an OMRON M3
upper-arm BP monitor (product code 031201; OMRON
Healthcare UK Ltd, Milton Keynes, UK), as well as meas-
ure height and weight, and collect other information
necessary to calculate CVD risk using the QRISK2 algo-
rithm. Smoking status will be assessed by patient self-
report and validated by measurement using a carbon
monoxide monitor (COmpact Smokerlyzer (product code
01420000); Bedfont Scientific, Maidstone, UK). A nonfast-
ing blood sample will be taken to determine the patient’s
total cholesterol to high-density lipoprotein cholesterol ra-
tio. If the patient has had this test conducted within the
previous 3 months, however, the existing result will be
used and the blood test will not be repeated. The CVD
risk assessment information will then be sent to the re-
search team, and used to calculate a QRISK2 10-year risk
score and verify the presence of at least one modifiable
risk factor. Patients will be contacted by e-mail or tele-
phone to inform them of their eligibility status.
In the depression trial, the research team will tele-
phone patients who have a total PHQ-9 score ≥10 on
the questionnaire to conduct further eligibility screening.
During the call, the researcher will conduct the CIS-R
screening assessment to establish whether the patient
has a confirmed diagnosis of depression. This measure
has been validated for telephone completion [22]. The
researcher will then immediately confirm eligibility.
Consent, baseline assessment and randomisation
Patients confirmed as eligible will be asked to complete
a consent form and a baseline assessment questionnaire.
This can be done online or by post. Once both have
been completed and received, patients will be randomly
allocated in a 1:1 ratio to receive either (1) usual care
plus the NHS Direct Healthlines Service (intervention
group) or (2) usual care alone (control group). Patients
will be allocated using an automated web randomisation
system to ensure concealment from research staff. Ran-
domisation will be stratified by location of recruitment
and minimised by practice and baseline CVD risk or de-
pression score, retaining a probabilistic element by using
a computer-generated random number sequence. The
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24.9, 25.0 to 29.9 and ≥30.0, and for PHQ-9 score they
are 10 to 14, 15 to 19 and ≥20 [21].
Communication following allocation
Participants in both trials will be notified of their alloca-
tion by e-mail. Their GP will also be informed of their par-
ticipation in the study, their allocation and their baseline
scores. Participants in the intervention group will be sent
a link to the NHS Direct Healthlines Service website,
where they will be provided with additional information
about the study intervention. The participants’ details will
be passed to the NHS Direct intervention team, and a
member of the intervention team will contact the patient
by telephone to conduct an initial assessment. Participants
in the intervention group in the CVD risk trial who have
raised BP and do not also have atrial fibrillation will be
offered a home BP monitor to use during the study. Pre-
trained practice staff will provide a short training session
to ensure the participant knows how to use the monitor.
Trial run-in phase
The run-in phase of the trial will commence recruitment
1 month ahead of the main trials. Two general practices
will be involved, and each will aim to recruit twenty pa-
tients to the depression trial and twenty to the CVD risk
trial. The purposes of the run-in phase are to test study
recruitment and follow-up procedures and to allow ad-
justments before the main trials if required. These steps
will also allow intervention staff to develop their skills in
using the intervention software and treatment protocols.
In order to provide intervention staff with a larger num-
ber of participants to work with during the run-in phase,
allocation in this phase will be at a ratio of 3:1 in favour
of the intervention group. Data collection and interven-
tion schedules will be the same for run-in phase partici-
pants as in the main trials, so data provided by these
participants will be included in the final trial analysis un-
less substantial changes to the trial protocol are required
between the run-in phase and the main trial.
MRC START in Healthlines substudy
The Medical Research Council Systematic Techniques for
Assisting Recruitment to Trials (MRC START) study is a
programme of research funded by the Medical Research
Council Methodology Programme, which is designed to
develop the conceptual, methodological and logistical fra-
mework for nested studies and to assess their feasibility
[23]. The Healthlines Study is acting as a host trial for one
of the MRC START recruitment interventions. Its aim is
to test the impact of an enhanced patient information
sheet and invitation letter on recruitment rates [24]. We
aim to carry out this substudy in up to four GP practices
at the Bristol site only.NHS Direct Healthlines intervention
Intervention staff
The Healthlines intervention will be delivered by a team
of NHS Direct health information advisors (HIAs).
These staff will be existing NHS Direct employees based
within an existing NHS Direct call centre. All the HIAs
will have a minimum of a diploma-level qualification or
equivalent experience in a healthcare or social care set-
ting. They will also have experience working for NHS
Direct in providing expert health and medication infor-
mation. The HIAs will receive 3 weeks of training prior
to delivering the Healthlines intervention. This training
will include classroom sessions, hands-on training and
side-by-side call reviews with expert training staff. It will
cover health coaching skills, training on how to intro-
duce and support the online or workbook CBT package
for depression, how to use CVD risk intervention soft-
ware and condition-specific knowledge and medicines
training, with the latter being delivered by expert phar-
macists. Throughout delivery, the Healthlines advisors
will have access to clinical advice and management sup-
port as required. Staff performance will also be moni-
tored using a rigorous call review process.
Hours and mode of operation
The NHS Direct Healthlines Service will be available
from Monday to Friday from 10 AM to 8 PM and on
Saturday from 10 AM to 2 PM. The service will provide
an initial assessment followed by regular telephone con-
tacts at prearranged appointment times. Where possible,
all contacts with an individual patient will be made by
the same staff member in order to promote continuity
of care and build rapport. The work of intervention staff
will be supported by computer software, which will be
used to guide the content of the telephone calls and cre-
ate a record of what was discussed. In addition, patients
will be able to request a call-back between their sched-
uled appointments via the intervention website or by
leaving a telephone voice mail message.
Initial assessment
An initial telephone assessment will be conducted to
provide further information about the NHS Direct
Healthlines Service and the treatment options available
to the participant. Relevant medical history and medica-
tion use will also be recorded. The next scheduled ap-
pointment will be arranged, and a report will be sent to
the participant’s GP.
Intervention content
The content of the intervention was developed to reflect
the conceptual model (Figure 2). The model was created
by the Healthlines research team based on findings from
a systematic review of the characteristics of effective
Figure 2 Healthlines intervention conceptual model.
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and staff experiences of related initiatives [25] and a
patient survey of attitudes toward different types of tele-
health interventions. These studies were conducted in
the earlier phase of the Healthlines research programme.
Appropriate and evidence-based priorities for interven-
tion were also identified by reviewing UK treatment
guidelines for depression and CVD risk factors and rele-
vant research literature, including Cochrane reviews.
Furthermore, we compared our findings about important
components of the intervention model with other re-
lated models, such as the Chronic Care Model [26]. The
final conceptual model highlights the need to promote
self-management (including using established approaches
such as goal-setting, self-monitoring, information-sharing,
decision-making, relapse prevention and regular review),
optimisation of treatment (particularly titration of medica-
tions following protocols), coordination of care between
providers and methods designed to enhance the engage-
ment of patients and GPs.
The intervention is designed to address each of the
components of the model, with the particular types of
help offered to each participant being tailored to their
needs and preferences. The core of the intervention con-
sists of regular telephone calls from a HIA, who sup-
ports the participant in setting and addressing their
goals by using advice derived from computerised proto-
cols and support scripts. These scripts frequently guide
the participant to relevant resources that are available
on the Internet, including information from reliable
sources (particularly NHS Choices [27]), interactive pro-
grammes such as computerised CBT and relevant appsand widgets (for example, to help with giving up smok-
ing). Having identified a relevant resource, the HIA will
e-mail the participant a link to the relevant website or
resource or will send them information by post. The
HIA will also review the participant’s progress with re-
gard to each goal during subsequent calls, seeking to en-
hance the participant’s motivation.
The intervention also includes access to an individualised
password-protected page of the NHS Direct Healthlines
Service web portal. This portal provides more information
about the service and about the participant’s health condi-
tion (CVD risk or depression), enables participants with
raised BP to record their BP readings and has links to other
resources.
Development of the NHS Direct Healthlines Service in-
corporated findings of a usability and acceptability study
conducted by NHS Direct. The overall aim of that study
was to explore the utility, usability and acceptability of the
proposed services for people with depression and raised
CVD risk. Three deliberative panels comprising eleven pa-
tients were convened, and ten in-depth interviews were
conducted with patients with either depression or raised
CVD risk. The patients were recruited from one GP prac-
tice in the Southampton area. The study explored patient
perspectives about the usefulness, benefits and drawbacks
of the intervention and how the service could be used by
patients to achieve specified goals within the context of its
specified purpose. Accessibility issues related to the service
were also discussed to help the research team understand
potential barriers to using the service.
In the CVD risk trial, the software and telephone scripts
were adapted from effective interventions developed by
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NC, USA) [28,29]. The content and language of this ori-
ginal intervention was modified where appropriate to
make it consistent with UK treatment guidelines and
the NHS environment and to incorporate additional
components written by the NHS Direct Clinical Con-
tent Team and CS. The software guides the delivery of a
series of modules during 12 telephone contacts appro-
ximately 4 weeks apart over a 12-month period. The
modules cover a wide variety to topics associated with
the management of raised CVD risk. The software is de-
signed so that the intervention staff covers topics which
are relevant to the patient during each telephone con-
tact, and the content of later encounters reflects the
topics that were covered in earlier calls. A list of the
modules is given below:
 Knowledge about cardiovascular risk and healthy
lifestyles
 Medication and side effects review
 Blood pressure medication optimisation
 Home blood pressure monitoring
 Statin medication review
 Support for medication adherence
 Smoking and nicotine replacement therapy
 Diet
 Weight loss and orlistat use
 Alcohol use
A key aspect of the CVD risk intervention is support
for home BP monitoring. Patients with a systolic BP
≥140 who do not have atrial fibrillation will be offered
an OMRON M3 home BP monitor. This device is a
basic monitor validated for home use by the European
Society of Hypertension International Protocol [30]. Par-
ticipants will be given instructions on how and when to
record their BP and how to enter their readings on the
Healthlines web portal. Participants are requested to
take BP readings twice daily for the first week and
weekly thereafter. The web portal calculates average
readings initially over the previous 6 days (if the partici-
pant has entered at least four readings) and then over
the previous 6 weeks. The participant is then automatic-
ally advised whether their BP is above their target, when
to take their BP again and what to do if their BP is too
high or too low. Target BP is based on UK National In-
stitute for Health and Care and Excellence (NICE)
guidelines [31], but it can be modified for individual pa-
tients by their GPs. The HIA will review the patient’s BP
readings during each monthly call. If the readings are
above target, the HIA will advise the patient to see his
or her GP and send the GP a letter asking the GP to
review the patient’s treatment, including a copy of the
relevant NICE guidelines about recommended steps forintensifying treatment. A copy of this letter will also be
available to the patient via the web portal.
In the depression trial, participants will be offered access
to the Living Life to the Full Interactive programme, sup-
ported by regular telephone contact. Living Life to the Full
Interactive is an online interactive multimedia programme
that delivers CBT-based treatment for depression (or co-
morbid depression and anxiety). It was developed by Chris
Williams of the University of Glasgow, UK [32,33]. It in-
volves six self-directed sessions completed approximately
every 2 weeks. The programme is offered to Healthlines
participants either as an online interactive programme
provided by Media Innovations Ltd (http://www.llttfi.com/)
or by giving them the Overcoming Depression and Low
Mood: A Five Areas Approach workbook to use [34]. As in
the CVD risk trial, at the core of the intervention is regular
telephone calls from HIAs at the NHS Direct Healthlines
Service designed to support participants in making use of
the materials available mainly via the Internet. The tele-
phone scripts used during each contact were written by the
NHS Direct Clinical Content Team and CS and incorporate
protocols for providing support to participants in using and
applying Living Life to the Full Interactive. In addition they
include modules covering monitoring of depression symp-
toms, optimising and stepping up treatment in cases of in-
adequate response, medication adherence, exercise and
alcohol use. Participants in the depression trial receive
seven telephone calls at approximately fortnightly intervals
over the course of 4 months, then two further contacts
made once every 3 months over the course of 6 months.
Participants will also have access to the Healthlines web
portal, which includes a link to the Living Life to the Full
Interactive programme. If they wish, they can also access
from the web-portal Big White Wall [35], a digital mental
health system with a 24/7 professionally managed peer sup-
port network.
In addition to the regular telephone calls and support
for using resources available online, the intervention in-
corporates several other features designed to address
components of the underlying theoretical model. Be-
cause one recognised problem with previous telehealth
interventions was low patient engagement, intervention-
mapping was used to identify features that would act as
barriers or facilitators to patient engagement. As a result,
the intervention has been designed to address perceived
barriers and highlight factors that would facilitate and
reinforce engagement. One factor discovered during the
developmental work to enhance patient engagement was
the importance of support from a named person rather
than from an impersonal call centre. Therefore, partici-
pants will be offered follow-up from the same HIA as
much as possible. Previous telehealth interventions have
also had problems related to engagement of primary care
clinicians [25]. The present research aims to address this
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working with primary care clinicians rather than dupli-
cating their efforts or competing with them. Accord-
ingly, letters are regularly sent to the GPs about each
patient’s progress during the course of the intervention.
Letters making recommendations about treatment are
also accessible to patients, which reinforces patient en-
gagement and may make it more likely that recommen-
dations will be acted upon.
Intervention completion
Patients can remain in receipt of the intervention for up
to 12 months. The final patient contact will include a
review of progress, information about other ongoing
sources of support and creation of a final summary to be
sent to the GP. Upon completion of interventions, par-
ticipants will be returned to the sole care of their GPs.
This transition will be clearly communicated to both the
participants and their GPs.
Outcome measurement
Primary outcomes
In both trials, the primary outcome will be the proportion
of patients who respond to treatment. In the CVD risk
trial, response to treatment is defined as the maintenance
or reduction of 10-year cardiovascular risk estimated on
the basis of QRISK2 score [20] after 12 months. Because
CVD risk increases with age, maintaining 10-year risk over
12 months requires an improvement in at least one modi-
fiable risk factor. Throughout the study, QRISK2 score will
be calculated using the same version of the QRISK2 algo-
rithm provided as a batch processor to the research team
by the authors of QRISK2. QRISK2 outcome scores will
be calculated by changing age and the modifiable risk fac-
tors only. Variables such as diagnosis of diabetes or atrial
fibrillation and whether the patient has been prescribed
BP-lowering medications will be held constant using base-
line values. This is because it is possible that the extra
support provided by the intervention may result in an in-
creased number of patients in the intervention arm receiv-
ing a diagnosis or starting medication, which in turn would
inflate risk scores in this group only. In the depression trial,
response is defined as a PHQ-9 score <10 and an absolute
reduction in PHQ-9 ≥5 after 4 months [21,36].
Secondary outcomes and process measures
Secondary outcomes and process measures are listed in
Table 1. These measures will be included in both trials
unless otherwise indicated.
Data collection and follow-up
Data will be collected from self-report questionnaires,
primary care medical records, NHS Direct Healthlines
Service records and clinical measurement. Informationwill be collected at baseline from all participants, but the
timing of follow-up data collection will differ between
the two trials (as detailed below). The primary method
of patient self-report data collection will be via online
questionnaires. However, alternative completion methods,
including on paper or by telephone, will be offered to
maximise response rates. The quality of life measure (EQ-
5D-5 L) will not be available for online completion, owing
to licensing and technical restrictions, and thus will be
completed on paper by all participants. Reminders com-
municated by e-mail, telephone and post will be used if
participants do not return their questionnaires. The base-
line questionnaire will include sociodemographic charac-
teristics, comorbidities, current treatments, employment
status and all secondary outcome measures. Follow-up
questionnaires will include primary and secondary out-
come measures and use of healthcare resources. Details
regarding medication prescriptions and primary care
contacts will be collected from primary care medical re-
cords for all participants 12 months after randomisa-
tion. For those in the intervention groups in both trials,
information about the type, number and length of contacts
with intervention staff will be collected from NHS Direct
Healthlines Service records. In addition, anonymised infor-
mation, including age, gender and ethnicity (both trials)
and CVD risk score and component data (CVD risk trial
only), will be obtained from practice records of invited pa-
tients who decided not to participate in the study.
In the CVD risk trial, self-report questionnaires will be
completed at three time points: at baseline and 6 and 12
months after randomisation. At each of these time points,
patients will also be asked to attend an appointment with
a nurse at their GP practice. The nurse will collect CVD
risk factor information, including a blood test to measure
cholesterol (at baseline and 12 months only), BP, weight
and smoking status (all time points). This information will
be used to calculate the individual QRISK2 score.
In the depression trial, self-report questionnaires will
be completed at four time points: at baseline and 4, 8
and 12 months after randomisation. The PHQ-9 ques-
tionnaire will be completed at each of these time points.
At baseline, it will be completed as part of an initial
screening questionnaire by post; at all other time points,
it will be included with the follow-up questionnaire and
therefore completed online or by post. Participants who
do not return their follow-up questionnaires will be con-
tacted by post and telephone to ask them to complete
the PHQ-9 alone.
Statistical considerations
Sample size
This study is based on analysis of data from 240 patients
in each of the intervention and control groups for both
the CVD risk and depression trials. The primary outcomes
Table 1 Secondary outcomes and process measures a
Outcomes Measures used
Depression score (depression trial only) as a binary outcome at 8
and 12 months and as a continuous variable at 4,8 and 12 months
PHQ-9 [21]
Ten-year CVD risk score (CVD risk trial only) as a binary outcome
at 6 months and as a continuous variable at 6 and 12 months
QRISK2 [19] variable obtained by clinical assessment
Quality of life EQ-5D-5 L [37]
Patient satisfaction Items constructed for present research and taken from Y4Q1 GP
Patient Survey
Patient perceived access to care Items adapted from TMQ [38] and items constructed for present research
Physical activity Health-directed behaviour domain of heiQ [39]
Individual cardiovascular risk factors that is blood pressure,
cholesterol, smoking status, weight, BMI (CVD risk trial only)
Clinical assessment
Diet (CVD risk trial only) STC [40] anglicised for present use
Use of telehealth Items constructed for present research
Internet use and experience Items constructed for present research
Self-management skills and self-efficacy Self-monitoring and insight, constructive attitudes and approaches, skill
and technique acquisition, and healthcare services navigation domains
of heiQ [39]
Medication adherence (depression trial asked only about
antidepressant medication; CVD trial asked about antihypertensive
and cholesterol-lowering medications)
Morisky Medication Adherence Scale [41]
Health literacy Items adapted from eHEALS [42]
Care coordination Subscales adapted from a measure of continuity questionnaire [43]
Anxiety (depression trial only) GAD-7 [44]
Resource use Items constructed for present research
Demographics Various items taken from the Y4Q1 GP Patient Survey, 2001 census and
Health Survey for England, 2007
aBMI, Body mass index; CVD, Cardiovascular disease; eHEALS, eHealth Literacy Scale; GAD-7, Generalized Anxiety Disorder 7-item scale; heiQ, Health Education
Impact Questionnaire; PHQ-9, Patient Health Questionnaire; STC, Starting the Conversation; TMQ, Treatment Motivation Questionnaire.
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sponse to the intervention. Assuming equal numbers in
each trial arm for analysis and that all other parameters in
a sample size estimate remain constant, the detectable
between-group difference for a binary outcome is maxi-
mised when the overall proportion in the trial defined as
responding is 50% (for example, 57% responding to NHS
Direct Healthlines interventions and 43% responding to
usual care). As the overall proportion responding increases
or decreases from 50%, so the detectable difference de-
creases. Thus, with a sample size for analysis of 240 per
arm, the absolute detectable difference between the trial
arms with a 5% two-sided α and 80% power is 14 percent-
age points or less (1.7 equivalent odds ratio). With a 1% α
and 90% power, it is 18 percentage points or less (2.1
equivalent odds ratio). For this trial, there is no accepted
minimum clinically important difference. Therefore, the
sample size was chosen pragmatically, taking into account
the size of effect that would be likely to influence policy
and practice and which might be feasible using this
intervention.
Regarding the CVD risk trial, a previous study reported
38% of treated hypertensive patients 60 to 80 years of agein a control group had a reduced absolute cardiovascular
risk at the 12-month follow-up examination [45]. Regard-
ing the depression trial, response to treatment using the
PHQ-9 is defined as a score <10 and a reduction of at least
5 points. In a previous trial involving a similar patient
group, the response in the control group was appro-
ximately 30% [46]. If the proportion in the control arm in
either of our trials is in the 30% to 38% range, 240 partici-
pants per arm for analysis will have 80% power (5% α) and
90% power (1% α) to detect differences of 13 and 18 per-
centage points, respectively.
Assuming 20% noncollection of primary outcome data
at follow-up, it will be necessary to recruit 300 patients
in each of the intervention and control groups for each
trial, or 1,200 patients in total.
Descriptive analysis
The analysis and presentation of each trial will be car-
ried out in accordance with Consolidated Standards of
Reporting Trials guidelines. Appropriate descriptive sta-
tistics will be used to compare characteristics of invited
patients who did or did not agree to take part and eli-
gible patients who were randomized or not randomized.
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tics at baseline across the trial groups.
Primary analysis
By using intention-to-treat analyses, we will compare
groups using logistic regression models adjusted for base-
line values of the outcome and stratification/minimisation
variables, paying attention to 95% confidence intervals as
well as P-values. Sensitivity analyses will be conducted
using standard techniques to impute missing data.
Secondary and subgroup analyses
Analysis of secondary outcomes, the effect of adherence
to the intervention and preplanned subgroup analyses
for the primary outcome will be conducted using appro-
priate multivariable regression models. The subgroups of
interest are age, sex and baseline CVD risk or PHQ-9
score. Subgroups broken down by the type of modifiable
risk factor at baseline (for example, high BP, obesity,
smoker) will be analysed in the CVD risk trial only. Add-
itional subgroups of interest may also be identified by the
process evaluation. Analysis of additional subgroups will
be agreed upon with the Data Monitoring Committee and
the Trial Steering Committee, and all analyses performed
will be reported. A full statistical analysis plan will be de-
veloped and agreed upon with the Trial Management
Group, the Data Monitoring Commitee and the Trial
Steering Committee prior to any analyses.
Protection against bias
Allocation will be concealed by use of a remote automated
system. Blinding of participants, HCPs and researchers is
not possible. We recognise that patients in the control
group may be able to access similar information from
other websites, including NHS Choices, although we think
that such usage will be much less than in the intervention
group because the latter will be directed to these resources
by NHS Direct Healthlines Services staff. We will collect
patient self-report information about the use of other rele-
vant web-based resources by all participants.
Research governance
Management, operational and academic aspects of the tri-
als are the responsibility of the Trial Management Group,
which meets approximately every 6 weeks. Conduct of the
trials will also be overseen by an Independent Trial Steer-
ing Committee and an Independent Data Monitoring
Committee. The whole research programme is also over-
seen by the Healthlines Programme Management Group,
which includes all the coapplicants on the programme
grant and patient and public representatives. The Univer-
sity of Bristol is the study sponsor, and the study has been
approved by the National Research Ethics Service Com-
mittee South West–Frenchay (Reference 12/SW/0009).Economic evaluation
The aim of the economic evaluation will be to estimate
the costs and benefits of the NHS Direct Healthlines
intervention in managing patients with raised CVD risk
or with depression and to assess the cost-effectiveness of
the telehealth packages in these contexts. There will be
two stages of this evaluation: (1) patient-level evaluations
covering the period of the trial and (2) modelling of fu-
ture costs and benefits to cover the lifetime of the trial
population. The patient-level evaluations will be carried
out prospectively alongside the depression and CVD risk
trials. These evaluations will take into account the per-
spectives of the healthcare provider (NHS) and personal
social services (PSS), patients and lost productivity due
to time taken off from work.
Identifying resource use
NHS resource use will include any care related to the
participant’s condition. For patients with depression, pri-
mary and community care is wide-ranging, thus we will
include all contacts with GPs, other doctors (such as
community psychiatrists), all nurses based in GP prac-
tices and in the community, and other HCPs (such as
counsellors, psychologists and occupational therapists).
Relevant medications will be identified using prespeci-
fied British National Formulary (BNF) codes [47]. Rele-
vant secondary care and PSS use will be identified by
patients as being sought out “because of mental health
or emotional problems”. For patients with raised CVD
risk, resource use will be restricted to contacts related to
high BP, high cholesterol, giving up smoking or over-
weight. NHS resource use will include all primary care,
medication and secondary care.
Personal out-of-pocket expenditures will vary by con-
dition. For patients with depression, this will include the
use of private healthcare and therapies, exercise specific-
ally aimed at improving mental health and domestic help
and travel. For those with raised CVD risk, this will in-
clude the use of private healthcare and therapies, home
BP monitors, smoking advice and strategies, exercise
aimed at reducing BP and cholesterol, weight loss pro-
grammes and travel. Resources used in setting up and
delivering the intervention will be identified during the
trial and documented by NHS Direct.
Measuring resource use
Where possible, data on primary care use and medica-
tion will be extracted from GPs’ notes. Data on other re-
source use, including personal expenditures and time
taken off from work, will be collected using the ques-
tionnaires administered as part of the data collection
programme within the trial follow-up. These question-
naires will be completed at 4, 8 and 12 month by pa-
tients with depression and at 6 and 12 months by those
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set up and run the Healthlines intervention will be re-
corded as part of the trial process.
Valuing resource use
NHS resources will be valued using nationally recognised
sources such as Curtis [48], the Department of Health
Tariff [49] and the BNF [47]. Patients will self-report per-
sonal costs. Time taken off from work will be valued using
the Annual Survey of Hours and Earnings published by the
Office for National Statistics [50]. The intervention will
be costed using data collected during the trial and sup-
plemented by information supplied by NHS Direct. The
startup costs will be identified and estimated separately
from the running costs, and the cost of each element of the
intervention will be estimated separately.
Sensitivity analysis
We will address any areas of uncertainty in structural as-
sumptions using a series of one-way sensitivity analyses.
Cost-effectiveness
Costs will be compared with benefits measured using the
primary outcomes of QRISK2 for patients with raised
CVD risk and PHQ-9 for those with depression. In both
cases, we will compare costs with quality-adjusted life
years (QALYs) derived from the EQ-5D-5 L. QALYs will
be calculated by valuing the health states on the EQ-5D-
5 L using the “cross-walk” between the EQ-5D-3 L value
sets and the EQ-5D-5 L as recommended by the EuroQol
group [37]. These sets are based on the valuations pro-
vided by a sample of the UK population. Incremental cost-
effectiveness ratios will be obtained for each patient group.
Uncertainty regarding these ratios will be captured by
using the bootstrapping technique and estimating the net
monetary benefit.
In the second stage of the economic evaluation, we
will use data from the trial along with other data in the
literature to develop simulation models similar to that
used in the Department of Health modelling of vascular
checks [51]. These models will be used to estimate cost
per QALY over the life of the trial population and indi-
cate parameters of importance in implementation of the
programme at the national level.
Parameters for both models will include the uptake,
effectiveness and cost of the different components of the
intervention package. They will also include the pre-
valence of the conditions, probability of disease pro-
gression (for example, developing severe depression or
experiencing a cardiovascular event), mortality associ-
ated with each health state, age, sex, socioeconomic sta-
tus and other risk factors for CVD, such as smoking.
Quality of life for each health state, as well as the cost of
relevant treatments, will be estimated using data fromthe trial and the literature. Costs and benefits will be dis-
counted in line with current recommendations prevail-
ing at the time [52].
Threshold analysis will be performed to identify re-
quired uptake, effectiveness and cost of the package for
the intervention to be cost-effective for given levels of
prevalence. We will also aim to identify subgroups of
high-risk patients for whom the intervention is most ap-
propriately targeted [53].
Embedded qualitative study
Qualitative research undertaken alongside a trial can
consider the acceptability of the intervention as well as
facilitators and barriers to the delivery of, use of and
compliance with the intervention [54]. The perspectives
of both patients and HCPs can be sought.
Design, methods and setting
We will undertake a qualitative interview study with HCPs
involved in delivering care to patients with the two condi-
tions and with patients in the intervention groups of the
trials. Face-to-face semistructured interviews with patients
and a mix of face-to-face and telephone interviews with
HCPs involved in delivering care will be conducted.
Sampling
To include practices serving populations with different
levels of deprivation, six of the general practices involved
in the trials will be selected to take part in the embedded
qualitative study: one in Bristol, one in Southampton
and four in Sheffield. Between 15 and 25 interviews will
be undertaken with HCPs offering care to participants
within the trial, including NHS Direct staff, GPs and
practice nurses from the six selected practices, and 20 to
30 participants in the intervention arm of the trial will
also be interviewed. A purposive sampling strategy will
be used by condition to ensure half of interviewees have
depression and half have risk factors for CVD. Next,
maximum variation sampling will be used so that pa-
tients of different socioeconomic backgrounds, gender
and age are interviewed.
Recruitment
HCPs in selected practices and NHS Direct Healthlines
Service staff will be sent a letter of invitation, information
sheet and consent form, which they will return if they wish
to participate. Sampled patients participating in the trials
who, as part of the trial consent, have agreed that they
could be approached to consider taking part in an inter-
view will be sent an information sheet and consent form.
Data collection
HCP interviews will be conducted at different times dur-
ing the trial period. Interviews will commence after the
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interviewed at least 6 months after randomisation. The
focus of the interviews will be on the intervention: its
perceived utility, problems that arise, issues that enhance
or hinder its operation in practice, and adherence. An
interview topic guide will be used. Interviews with HCPs
will take place at their workplaces, or by telephone if
that is more convenient. Interviews with patients will
take place at their homes or at their general practice, de-
pending on their preference.
Analysis
Interviews will be recorded and transcribed verbatim.
Framework analysis will be used. The thematic frame-
work will be informed partly by issues that arise in early
phases of the programme and partly by themes that
emerge from the interviews.
We also plan to combine elements of the qualitative
study with some of the quantitative results within a
mixed-methods process evaluation to explore issues re-
lated to implementation, fidelity to the intervention
model, factors which appeared to act as barriers to and
facilitators of the success of the intervention and which
aspects of the intervention the patients and practitioners
felt were most and least successful.
Discussion
There is a need for new, efficient, effective interventions
to support the growing number of people living with
LTCs. This study will evaluate one such intervention de-
livered using the telephone, Internet and home monitor-
ing. Previous research on similar telehealth interventions
have been criticised for the lack of theoretical underpin-
ning and for failing to adequately evaluate the impact on
health outcomes, patient satisfaction, use of health ser-
vices and cost of delivery. We aim to address these criti-
cisms. Our intervention is theory-based and combines a
number of intervention components for which there is
already some evidence of effectiveness (for example,
computerised CBT or home BP monitoring) [29,55-57].
Use of a conceptual model to guide intervention design
is a strength of the study, as it will allow us to explore
the mechanism of action. In addition, carrying out two
linked trials provides the opportunity to evaluate the
intervention in two contrasting patient groups. If the
intervention is found to be effective in both patient
groups, confidence in the efficacy of the underlying the-
oretical model would be increased, suggesting that suc-
cessful interventions for other LTCs could be designed
based on the same model. The study will also incorporate
a variety of methods, including a qualitative interview
study, economic evaluation and economic modelling, in
order to maximise understanding of the findings and
lessons for future commissioning and implementation.Working with NHS Direct, an existing NHS organisation
with an established infrastructure and expertise in the de-
sign and delivery of telephone- and Internet-based health-
care, is a further strength of the study. Setting up this
complex study within the time frame and budget of a re-
search programme has presented a number of challenges.
These challenges have included introducing a new service
during a time of major NHS reorganisation and appropri-
ately adapting software developed in the United States and
integrating it with additional new software designed by
NHS Direct. NHS Direct and the research team have
worked hard to overcome these challenges. We feel that
this large, multicentre, pragmatic study with a multi-
method design will make a positive contribution to the
evidence base for telehealth interventions.
Trial status
Recruitment of general practices commenced in April
2012. Participant randomisation commenced in July 2012
and was completed on 31 July 2013.
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